Derek Ostertag

发表

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Harry E. Gruber, Joan M. Robbins, J. Hlavaty, 2011, Neuro-oncology.

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

William P. Accomando, T. Mikkelsen, T. Cloughesy, 2018, Neuro-oncology.

SHEP1 partners with CasL to promote marginal zone B-cell maturation

E. Pasquale, R. Rickert, D. Ostertag, 2010, Proceedings of the National Academy of Sciences.

Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer

N. Kasahara, D. Jolly, D. Ostertag, 2021, Expert opinion on biological therapy.

Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients

Jay-Jiguang Zhu, A. Das, H. Gruber, 2018, Clinical Cancer Research.

Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

Masamichi Takahashi, K. Hiraoka, N. Kasahara, 2017, Neuro-oncology.

JNK2 and IKKbeta are required for activating the innate response to viral infection.

M. Karin, Lufen Chang, Zhi-wei Li, 1999, Immunity.

Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma

Ash A. Alizadeh, Aliz R. Rao, Aaron M. Newman, 2020, Clinical Cancer Research.

Overproduction of Double-Stranded RNA in Vesicular Stomatitis Virus-Infected Cells Activates a Constitutive Cell-Type-Specific Antiviral Response

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006, Journal of Virology.

MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.

M. Hanna, D. Ostertag, O. Diago, 2016, Epigenomics.

MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.

N. Kasahara, C. Logg, Shuichi Kamijima, 2014, Human gene therapy.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

D. Jolly, D. Ostertag, O. Diago, 2016, Human gene therapy methods.

Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.

N. Kasahara, F. Hofman, H. Gruber, 2015, Human gene therapy.

SHEP1 partners with CasL to promote marginal zone B-cell maturation

E. Pasquale, R. Rickert, Y. Wallez, 2010, Proceedings of the National Academy of Sciences.

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

T. Mikkelsen, T. Cloughesy, L. Liau, 2016, Science Translational Medicine.

Cell-Type-Specific Growth Restriction of Vesicular Stomatitis Virus polR Mutants Is Linked to Defective Viral Polymerase Function

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006, Journal of Virology.

Cell type-specific growth restriction of vesicular stomatitis virus polR 1 mutants is linked to defective viral polymerase function 2 3 Running title : Cell type-specific growth restriction of VSV polR 4 5

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006 .

Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model

W. Günzburg, H. Petznek, J. Hlavaty, 2013, Cancer Gene Therapy.

Encouraging survival with Toca 511 and Toca FC compared to external lomustine control.

T. Mikkelsen, T. Cloughesy, J. Landolfi, 2016 .